Dupixent™ (dupilumab) now publicly reimbursed in quebec for moderate-to-severe atopic dermatitis

The Eczema Society of Canada is happy to share the exciting news that Dupixent™ (dupilumab), the first biologic therapy for the treatment of moderate-to-severe atopic dermatitis, is now reimbursed in Quebec. Quebec is the first province in Canada to offer public reimbursement for this treatment.

“People living with moderate-to-severe atopic dermatitis often experience chronic, intense, and sometimes unbearable symptoms that can significantly impact their daily lives,” says Amanda Cresswell-Melville, Executive Director of the Eczema Society of Canada. “The Quebec reimbursement addresses the growing need for greater access to treatment options that can help to improve the lives of patient suffering with a more severe form of atopic dermatitis. This is excellent news for atopic dermatitis patients in Quebec.”

For more information on this announcement, visit: https://www.newswire.ca/news-releases/patients-in-quebec-now-have-access-to-dupixent-tm-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-856511538.html

If you live with eczema and want to learn more about this option, speak with your doctor about your treatment plan and visit our treatments page.